
Allarity Therapeutics (ALLR) Stock Forecast & Price Target
Allarity Therapeutics (ALLR) Analyst Ratings
Bulls say
Allarity Therapeutics Inc is positioned favorably due to its ongoing development of stenoparib, which has demonstrated promising clinical benefits, including a median overall survival exceeding 25 months for patients in its Phase 2 trial. The company’s proprietary Drug Response Predictor (DRP) technology is enhancing patient selection and clinical outcomes, thereby strengthening its market potential in the oncology sector. Additionally, the current valuation reflects a significant upside, supported by a net present value (NPV) analysis that indicates an attractive investment opportunity, even while acknowledging the associated high risks.
Bears say
Allarity Therapeutics Inc reported a net loss of $2.8 million, translating to an earnings per share (EPS) of $(0.19), which was slightly better than estimates but still indicative of ongoing financial challenges. The company also faced similar losses of $2.37 million in previous quarters, further underscoring a consistent pattern of negative earnings performance. Compounding these financial setbacks are significant risks including liquidity challenges, regulatory hurdles, and competitive pressures, which contribute to a negative outlook for the company's stock.
This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction
Start investing in Allarity Therapeutics (ALLR)
Order type
Buy in
Order amount
Est. shares
0 shares